Skip to main
  1. Stocks
  2. Turn Therapeutics Inc
  3. Forecast
TTRX

TTRX Stock Forecast & Price Target

TTRX Analyst Ratings

Based on 3 analyst ratings
Buy
Strong Buy 67%
Buy 0%
Hold 33%
Sell 0%
Strong Sell 0%

Bulls say

Turn Therapeutics is attractive because its PermaFusion® platform addresses a core topical-drug limitation by delivering liquid APIs as stable nanodroplets with deep penetration, preserved potency, and reduced side effects, while remaining API-agnostic across dermatology, infectious disease, and vaccines. GX-03 adds conviction: it has been validated across three FDA-cleared medical devices, supported by over 200,000 human uses with no reported adverse events, and is now in a 120-135 patient Phase 2 eczema trial that began in July 2025 with no safety or tolerability concerns reported to date. The company also has meaningful non-dilutive upside from partnerships, including up to $69.55 million in milestones plus mid-single digit royalties from Mimedx and a 2025 Medline agreement, which together help fund development while preserving capital efficiency.

Bears say

Turn Therapeutics is a clinical-stage biotech with promising GX-03 data, but the investment case is weakened by the long, expensive road from Phase 2 to Phase 3 and the likelihood that near-term upside is already reflected in the current share price. The company faces meaningful financing risk, including a GEM facility for up to $85.0 million at 90% of the average closing price over 15 trading days, which signals potential dilution and may still fall short of future capital needs. In addition, fewer than 100,000 shares have traded on most days, Bradley Burnam controlled about 52% of voting power as of June 30, 2025, and unresolved legal, supply-chain, and contractor dependencies add execution risk.

TTRX has been analyzed by 3 analysts, with a consensus rating of Buy. 67% of analysts recommend a Strong Buy, 0% recommend Buy, 33% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Turn Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

TTRX Analyst Forecast & Price Prediction

Get the latest TTRX stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in TTRX

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Turn Therapeutics Inc (TTRX) Forecast

Analysts have given TTRX a Buy based on their latest research and market trends.

According to 3 analysts, TTRX has a Buy consensus rating as of Nov 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $14, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $14, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Turn Therapeutics Inc (TTRX)


TTRX Analyst Forecast & Price Prediction

Get the latest TTRX stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in TTRX

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover TTRX stock data and trends